25 research outputs found
A Calanais myth and an alignment of the east stone-row with both the rising of the Pleiades and crossovers of Venus at sunrise on the summer solstices
Acknowledgements My thanks to Stefan Sagrott of Historic Environment Scotland for his help in obtaining Patrick Ashmoreâs data and to David Forrest, School of Geographical and Earth Sciences, University of Glasgow, for providing a copy of David Taitâs map of Calanais.Peer reviewedPublisher PD
Corrigendum: Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus (vol 10, 1151, 2019)
Reference 86 was also included as âEscacena N. Cellular
medication as a therapeutic alternative in chronic critical
limb ischemia in diabetic patients without the possibility of
revascularization. Dissertation Thesis. Sevilla Spain: University
of Sevilla. (2016)â. This reference should be included as number
107 âEscacena N. Cellular medication as a therapeutic alternative
in chronic critical limb ischemia in diabetic patients without the
possibility of revascularization (Dissertation Thesis). University of
Sevilla, Seville, Spain (2016).
Corrigendum: Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus (vol 10, 1151, 2019)
Reference 86 was also included as âEscacena N. Cellular
medication as a therapeutic alternative in chronic critical
limb ischemia in diabetic patients without the possibility of
revascularization. Dissertation Thesis. Sevilla Spain: University
of Sevilla. (2016)â. This reference should be included as number
107 âEscacena N. Cellular medication as a therapeutic alternative
in chronic critical limb ischemia in diabetic patients without the
possibility of revascularization (Dissertation Thesis). University of
Sevilla, Seville, Spain (2016).
Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
Cell therapy is a progressively growing field that is rapidly moving from preclinical model
development to clinical application. Outcomes obtained from clinical trials reveal the
therapeutic potential of stem cell-based therapy to deal with unmet medical treatment
needs for several disorders with no therapeutic options. Among adult stem cells,
mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for
the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety
and feasibility of autologous MSC-based therapy has been established; however, their
indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies.
While MSCs derived from diverse tissues share common properties depending on the
type of clinical application, they markedly differ within clinical trials in terms of efficacy,
resulting in many unanswered questions regarding the application of MSCs. Additionally,
our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that
the therapeutic efficacy of these cells in different animal models has only been partially
reproduced in humans through clinical trials. Therefore, it is crucial to develop new
research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms
used by these cells, as well as to be able to offer a next generation of stem cell that
can be routinely used in a cost-effective and safe manner in stem cell-based therapies
targeting CLI
Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
Cell therapy is a progressively growing field that is rapidly moving from preclinical model
development to clinical application. Outcomes obtained from clinical trials reveal the
therapeutic potential of stem cell-based therapy to deal with unmet medical treatment
needs for several disorders with no therapeutic options. Among adult stem cells,
mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for
the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety
and feasibility of autologous MSC-based therapy has been established; however, their
indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies.
While MSCs derived from diverse tissues share common properties depending on the
type of clinical application, they markedly differ within clinical trials in terms of efficacy,
resulting in many unanswered questions regarding the application of MSCs. Additionally,
our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that
the therapeutic efficacy of these cells in different animal models has only been partially
reproduced in humans through clinical trials. Therefore, it is crucial to develop new
research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms
used by these cells, as well as to be able to offer a next generation of stem cell that
can be routinely used in a cost-effective and safe manner in stem cell-based therapies
targeting CLI